Literature DB >> 28775045

Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris.

Boris Duchemann1,2, Isabella Annesi-Maesano3, Camille Jacobe de Naurois4, Shreosi Sanyal3, Pierre-Yves Brillet2,5, Michel Brauner5, Marianne Kambouchner6, Sophie Huynh7, Jean Marc Naccache8, Raphael Borie9, Jacques Piquet10, Arsène Mekinian11, Jerôme Virally7, Yurdagul Uzunhan1,2, Jacques Cadranel8, Bruno Crestani9, Olivier Fain11, Francois Lhote12, Robin Dhote13, Nathalie Saidenberg-Kermanac'h14, Paul-André Rosental15, Dominique Valeyre1,2, Hilario Nunes16,2.   

Abstract

The objective of the study was to estimate the prevalence and incidence of interstitial lung diseases (ILDs) in Seine-Saint-Denis, a multi-ethnic county of Greater Paris, France.Patients with ILDs were identified between January and December 2012 by using several sources; all potentially involved medical specialists from public and private hospitals, community-based pulmonologists and general practitioners, and the Social Security system. Diagnoses were validated centrally by an expert multidisciplinary discussion.1170 ILD cases were reported (crude overall prevalence: 97.9/105 and incidence: 19.4/105/year). In the 848 reviewed cases, the most prevalent diagnoses were sarcoidosis (42.6%), connective tissue diseases associated ILDs (CTDs-ILDs) (16%), idiopathic pulmonary fibrosis (IPF) (11.6%), and occupational ILDs (5.0%), which corresponded to a crude prevalence of 30.2/105 for sarcoidosis, 12.1/105 for CTDs-ILDs and 8.2/105 for IPF. The prevalence of fibrotic idiopathic interstitial pneumonias, merging IPF, nonspecific interstitial pneumonia and cases registered with code J84.1 was 16.34/105 An adjusted multinomial model demonstrated an increased risk of sarcoidosis in North Africans and Afro-Caribbeans and of CTDs-ILDs in Afro-Caribbeans, compared to that in Europeans.This study, with a comprehensive recruitment and stringent diagnostic criteria, emphasises the importance of secondary ILDs, particularly CTDs-ILDs and the relatively low prevalence of IPF, and confirms that sarcoidosis is a rare disease in France.
Copyright ©ERS 2017.

Entities:  

Mesh:

Year:  2017        PMID: 28775045     DOI: 10.1183/13993003.02419-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  32 in total

1.  Adolescent physical activity and inactivity vary by ethnicity: The National Longitudinal Study of Adolescent Health.

Authors:  P Gordon-Larsen; R G McMurray; B M Popkin
Journal:  J Pediatr       Date:  1999-09       Impact factor: 4.406

Review 2.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

Review 3.  Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review.

Authors:  John Hutchinson; Andrew Fogarty; Richard Hubbard; Tricia McKeever
Journal:  Eur Respir J       Date:  2015-05-14       Impact factor: 16.671

4.  Incidence and prevalence of idiopathic pulmonary fibrosis.

Authors:  Ganesh Raghu; Derek Weycker; John Edelsberg; Williamson Z Bradford; Gerry Oster
Journal:  Am J Respir Crit Care Med       Date:  2006-06-29       Impact factor: 21.405

5.  Epidemiology and survival of idiopathic pulmonary fibrosis from national data in Canada.

Authors:  Robert B Hopkins; Natasha Burke; Charlene Fell; Genevieve Dion; Martin Kolb
Journal:  Eur Respir J       Date:  2016-05-26       Impact factor: 16.671

6.  Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders.

Authors:  M Thomeer; M Demedts; K Vandeurzen
Journal:  Acta Clin Belg       Date:  2001 May-Jun       Impact factor: 1.264

7.  Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland.

Authors:  U Hodgson; T Laitinen; P Tukiainen
Journal:  Thorax       Date:  2002-04       Impact factor: 9.139

8.  Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK.

Authors:  J Gribbin; R B Hubbard; I Le Jeune; C J P Smith; J West; L J Tata
Journal:  Thorax       Date:  2006-07-14       Impact factor: 9.139

Review 9.  Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature.

Authors:  Luba Nalysnyk; Javier Cid-Ruzafa; Philip Rotella; Dirk Esser
Journal:  Eur Respir Rev       Date:  2012-12-01

10.  Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11.

Authors:  Ganesh Raghu; Shih-Yin Chen; Wei-Shi Yeh; Brad Maroni; Qian Li; Yuan-Chi Lee; Harold R Collard
Journal:  Lancet Respir Med       Date:  2014-05-27       Impact factor: 30.700

View more
  45 in total

1.  Unusual cause of recurrent macroscopic hematuria in an adolescent girl: Answers.

Authors:  Abir Boussetta; Manel Jellouli; Raja Aouaidia; Rim Goucha; Taher Gargah
Journal:  Pediatr Nephrol       Date:  2020-11-27       Impact factor: 3.714

Review 2.  Sarcoidosis: a review for the internist.

Authors:  Elena Bargagli; Antje Prasse
Journal:  Intern Emerg Med       Date:  2018-01-03       Impact factor: 3.397

3.  African-American race and mortality in interstitial lung disease: a multicentre propensity-matched analysis.

Authors:  Ayodeji Adegunsoye; Justin M Oldham; Shashi K Bellam; Jonathan H Chung; Paul A Chung; Kathleen M Biblowitz; Steven Montner; Cathryn Lee; Scully Hsu; Aliya N Husain; Rekha Vij; Gokhan Mutlu; Imre Noth; Matthew M Churpek; Mary E Strek
Journal:  Eur Respir J       Date:  2018-06-14       Impact factor: 16.671

4.  Derivation and Validation of a Diagnostic Prediction Tool for Interstitial Lung Disease.

Authors:  Janelle Vu Pugashetti; Aleksander Kitich; Shehabaldin Alqalyoobi; Anne-Catherine Maynard-Paquette; David Pritchard; Julia Graham; Noelle Boctor; Andrea Kulinich; Elyse Lafond; Elena Foster; Cesar Mendez; Saad Choudhry; Jean Chalaoui; Julie Morisset; Michael Kadoch; Justin M Oldham
Journal:  Chest       Date:  2020-03-14       Impact factor: 9.410

5.  MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.

Authors:  Pierre-Antoine Juge; Joyce S Lee; Esther Ebstein; Hiroshi Furukawa; Evgenia Dobrinskikh; Steven Gazal; Caroline Kannengiesser; Sébastien Ottaviani; Shomi Oka; Shigeto Tohma; Naoyuki Tsuchiya; Jorge Rojas-Serrano; Montserrat I González-Pérez; Mayra Mejía; Ivette Buendía-Roldán; Ramcés Falfán-Valencia; Enrique Ambrocio-Ortiz; Effrosyni Manali; Spyros A Papiris; Theofanis Karageorgas; Dimitrios Boumpas; Katarina Antoniou; Coline H M van Moorsel; Joanne van der Vis; Yaël A de Man; Jan C Grutters; Yaping Wang; Raphaël Borie; Lidwine Wemeau-Stervinou; Benoît Wallaert; René-Marc Flipo; Hilario Nunes; Dominique Valeyre; Nathalie Saidenberg-Kermanac'h; Marie-Christophe Boissier; Sylvain Marchand-Adam; Aline Frazier; Pascal Richette; Yannick Allanore; Jean Sibilia; Claire Dromer; Christophe Richez; Thierry Schaeverbeke; Huguette Lioté; Gabriel Thabut; Nadia Nathan; Serge Amselem; Martin Soubrier; Vincent Cottin; Annick Clément; Kevin Deane; Avram D Walts; Tasha Fingerlin; Aryeh Fischer; Jay H Ryu; Eric L Matteson; Timothy B Niewold; Deborah Assayag; Andrew Gross; Paul Wolters; Marvin I Schwarz; Michael Holers; Joshua J Solomon; Tracy Doyle; Ivan O Rosas; Cornelis Blauwendraat; Mike A Nalls; Marie-Pierre Debray; Catherine Boileau; Bruno Crestani; David A Schwartz; Philippe Dieudé
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

Review 6.  Epidemiology of sarcoidosis: current findings and future directions.

Authors:  Elizabeth V Arkema; Yvette C Cozier
Journal:  Ther Adv Chronic Dis       Date:  2018-08-24       Impact factor: 5.091

7.  Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study).

Authors:  Mouhamad Nasser; Sophie Larrieu; Loic Boussel; Salim Si-Mohamed; Fabienne Bazin; Sébastien Marque; Jacques Massol; Françoise Thivolet-Bejui; Lara Chalabreysse; Delphine Maucort-Boulch; Eric Hachulla; Stéphane Jouneau; Katell Le Lay; Vincent Cottin
Journal:  Respir Res       Date:  2021-05-24

8.  Associations of ω-3 Fatty Acids With Interstitial Lung Disease and Lung Imaging Abnormalities Among Adults.

Authors:  John S Kim; Brian T Steffen; Anna J Podolanczuk; Steven M Kawut; Imre Noth; Ganesh Raghu; Erin D Michos; Eric A Hoffman; Gisli Thor Axelsson; Gunnar Gudmundsson; Vilmundur Gudnason; Elias F Gudmundsson; Rachel A Murphy; Josée Dupuis; Hanfei Xu; Ramachandran S Vasan; George T O'Connor; William S Harris; Gary M Hunninghake; R Graham Barr; Michael Y Tsai; David J Lederer
Journal:  Am J Epidemiol       Date:  2021-01-04       Impact factor: 4.897

Review 9.  Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD.

Authors:  John N Shumar; Abhimanyu Chandel; Christopher S King
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

10.  Sarcoidosis-Like Cancer-Associated Granulomatosis: Characteristics and a Case-Control Comparison with Sarcoidosis.

Authors:  Jean Pastré; Diane Bouvry; Karine Juvin; Amira Benattia; Isabella Annesi-Maesano; Dominique Valeyre; Hilario Nunes; Dominique Israël-Biet
Journal:  J Clin Med       Date:  2021-05-05       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.